These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 20403398)

  • 1. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
    Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
    J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
    Valencia-Serna J; Gul-Uludağ H; Mahdipoor P; Jiang X; Uludağ H
    J Control Release; 2013 Dec; 172(2):495-503. PubMed ID: 23726887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
    Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
    Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
    Withey JM; Harvey AJ; Crompton MR
    Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.
    Scherr M; Battmer K; Schultheis B; Ganser A; Eder M
    Gene Ther; 2005 Jan; 12(1):12-21. PubMed ID: 15602589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.
    Mendonça LS; Firmino F; Moreira JN; Pedroso de Lima MC; Simões S
    Bioconjug Chem; 2010 Jan; 21(1):157-68. PubMed ID: 20000596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
    Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
    Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
    Bártová E; Harnicarová A; Pacherník J; Kozubek S
    Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction of eukaryotic expression vector of siRNA specific to bcr/abl fusion gene].
    Xi YM; Liu T; Meng WT; Wang YH; Gu L; Lu XX; Gong YP
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jul; 36(4):460-3. PubMed ID: 16078560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
    Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
    J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
    Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
    J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression.
    Baker BE; Kestler DP; Ichiki AT
    J Biomed Sci; 2006 Jul; 13(4):499-507. PubMed ID: 16547768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
    Zaree Mahmodabady A; Javadi HR; Kamali M; Najafi A; Hojati Z
    Iran Biomed J; 2010; 14(1-2):1-8. PubMed ID: 20683492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
    Koldehoff M; Zakrzewski JL; Beelen DW; Elmaagacli AH
    Cancer Gene Ther; 2013 Jul; 20(7):421-7. PubMed ID: 23788109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.
    Elmaagacli AH; Koldehoff M; Peceny R; Klein-Hitpass L; Ottinger H; Beelen DW; Opalka B
    Haematologica; 2005 Mar; 90(3):326-34. PubMed ID: 15749664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
    Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
    Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.